HC Wainwright reissued their buy rating on shares of NASDAQ Other Finance (NASDAQ:OTHER) in a report released on Thursday. The firm currently has a $3.00 price objective on the stock.

“We consider this a significant milestone for the company and a crucial gating item for the potential near-term approval of the product for the first of what may be many uses in the surgical setting. This application could be approved in the U.S. by late 2017 or early 2018, in our view.”,” the firm’s analyst wrote.

Several other brokerages also recently commented on OTHER. Needham & Company LLC reaffirmed a buy rating and set a $8.50 price objective on shares of NASDAQ Other Finance in a research note on Thursday. Maxim Group reaffirmed a buy rating and set a $5.50 price objective on shares of NASDAQ Other Finance in a research note on Tuesday, July 25th. Jefferies Group LLC reaffirmed a buy rating and set a $20.00 price objective on shares of NASDAQ Other Finance in a research note on Friday, July 21st. Finally, BMO Capital Markets reaffirmed a buy rating and set a $32.00 price objective on shares of NASDAQ Other Finance in a research note on Thursday, April 20th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company has an average rating of Buy and a consensus price target of $12.21.

TRADEMARK VIOLATION NOTICE: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.watchlistnews.com/nasdaq-other-finance-other-rating-reiterated-by-hc-wainwright/1463846.html.

Analyst Recommendations for NASDAQ Other Finance (NASDAQ:OTHER)

Receive News & Ratings for NASDAQ Other Finance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NASDAQ Other Finance and related companies with Analyst Ratings Network's FREE daily email newsletter.